ストレプトゾトシン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H228：可燃性固体

  H341：遺伝性疾患のおそれの疑い

  H351：発がんのおそれの疑い

• 注意書き

  P201：使用前に取扱説明書を入手すること。

  P202：全ての安全注意を読み理解するまで取り扱わないこ と。

  P210：熱/火花/裸火/高温のもののような着火源から遠ざ けること。－禁煙。

  P240：容器を接地すること/アースをとること。

  P241：防爆型の電気機器/換気装置/照明機器/．．．機器を使 用すること。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

ストレプトゾトシン 価格

MSDS Information

• 2-Desoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose

ストレプトゾトシン 化学特性,用途語,生産方法

• 外観

  わずかにうすい黄色の粉末

• 溶解性

  水及びエタノール及びアセトンに溶ける。

• 解説

  ストレプトゾトシン,白色の結晶．分解点115 ℃．[α]²⁵_D＋39°(水)．UV(エタノール)λmax 228 nm(ε 6360)．抗腫瘍作用とグラム陽性菌，グラム陰性菌に対する抗菌作用があるが，臨床で使用されていない．分子内にニトロソウレイド基を含み，そのアルキル化作用でDNAを損傷する．アロキサンと同様，膵臓のランゲルハンス島のβ細胞を特異的に破壊し，ラットやマウスにインスリン欠乏型糖尿病を誘導する．糖尿病の病因や治療の研究に使用される．LD50 275 mg/kg(雄マウス，静注)．

  森北出版「化学辞典（第2版）
  

• 用途

  転移性の膵内分泌腫瘍の治療に使用される

• 用途

  ラット、マウスに投与し、実験的糖尿病モデルを作成します。

• 用途

  アミノグリコシド系抗生物質 です。ラットに投与すると膵 β 細胞を特異 的に破壊します。糖尿病モデル動物の作製に ご使用下さい。

• 効能

  抗悪性腫瘍薬, アルキル化剤

• 商品名

  ザノサー (ノーベルファーマ)

• 使用上の注意

  取り扱う場合は、保護眼鏡、保護手袋、及び保護マスクを用いて下さい。

• 説明

  Streptozotocin (STZ) was originally identified in the late 1950s as an antibiotic and was discovered in a strain of the soil microbe Streptomyces achromogenes. In the mid-1960s, STZ was found to be selectively toxic to the beta cells of the pancreatic islets and thus it is used in animal model of diabetes and as a medical treatment for cancers of the beta cells. STZ’s use in cancer chemotherapy received Food and Drug Administration approval in July 1982 and the drug was subsequently marketed as Zanosar.

• 化学的特性

  off-white to pale yellow crystalline powder

• 使用

  Streptozotocin is used in the treatment metastatic cancer of the pancreatic islet cells. Streptozotocin has a highlrisk of toxicity and is generally limited to cancers that are inoperable.

• 定義

  ChEBI: An antibiotic that is produced by Streptomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.

• 適応症

  Streptozocin (Zanosar), a water-soluble nitrosourea produced by the fungus Streptomyces achromogenes, acts through methylation of nucleic acids and proteins. In addition, it produces rapid and severe depletion of the pyridine nucleotides nicotinamide adenine dinucleotide (NAD) and its reduced form (NADH) in liver and pancreatic islets.
  Streptozocin is not well absorbed from the gastrointestinal tract and must be administered intravenously or intraarterially. In preclinical studies, the plasma half-life was 5 to 10 minutes.
  Streptozocin produces remission in 50 to 60% of patients with islet cell carcinomas of the pancreas. It is also useful in malignant carcinoid tumors.
  Almost all patients have nausea and vomiting. The major toxicity is renal tubular damage, which may be severe in 5 to 10% of patients taking streptozocin. Treatment of metastatic insulinomas may result in the release of insulin from the tumor and subsequent hypoglycemic coma. Less severe toxicities include diarrhea, anemia, and mild alterations in glucose tolerance or liver function tests.

• 一般的な説明

  Off-white powder. Melting point 115°C. Used as an anti-cancer drug. Carcinogenic.

• 空気と水の反応

  Water soluble.

• 反応プロフィール

  [D-GLUCOSE, 2-DEOXY-2-[[(METHYLNITROSOAMINO)-CARBONYL]AMINO] is weakly basic. Reacts exothermically with acids. Reacts with both strong oxidizing agents and strong reducing agents.

• 生物活性

  Antibiotic and antitumor agent. Alkylates DNA and induces diabetes mellitus via reduction of nicotinamide adenine dinucleotide in pancreatic β -cells in vivo .

• 臨床応用

  The glucopyranose moiety of streptozocin confers both islet cell specificity and high water solubility to this nitrosourea-based antineoplastic. As a result, it is used exclusively in metastatic islet cell carcinoma of the pancreas and is administered IV in D5W or normal saline.

• 副作用

  Lacking the 2-chloroethyl substituent of carmustine and lomustine, it is much less reactive as a DNA alkylating agent, and myelotoxicity is relatively rare but not unknown. Cumulative, dose-related renal toxicity can be severe or fatal, however, and 67% of patients receiving this drug will exhibit some kidney-related pathology.

• 安全性プロファイル

  Confirmed carcinogen with experimental carcinogenic, neoplas tigenic, tumorigenic, and teratogenic data. Experimental poison by intravenous, parenteral, subcutaneous, and intraperitoneal routes. Moderately toxic to humans by intravenous route. Human systemic effects: nausea or vomiting, impaired liver function, kidney changes. Human mutation data reported. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of NOx. See also NITROSAMINES.

• 発がん性

  Streptozotocin is reasonably anticipated to be a human carcinogenbased on sufficient evidence of carcinogenicity from studies in experimental animals.

• 環境運命予測

  STZ is an odorless ivory-colored crystalline powder or pale yellow crystals. Having the solubility of 5070 mg l^-1 in water at 25 °C, STZ is soluble in alcohol and ketones and slightly soluble in polar organic solvents and insoluble in nonpolar organic solvents. STZ is produced by the soil microorganism and therefore isolated from soil samples that assumed a source of release to the environment. Vapor pressure and Henry’s law constant of STZ are 1.74E-12 mm Hg and 1.08E-10 cm3 per molecule-sec at 25 °C, respectively. No information is currently available for partition behavior in water, sediment, and soil; environmental persistency, long-range transport, or bioaccumulation/ biomagnification.

• 純化方法

  Recrystallise streptozotocin from 95% EtOH. It is soluble in H2O, MeOH and Me2CO. It has UV max at 228nm ( 6360) in EtOH. The tetraacetate has m 111-114o(dec), and [] D 25 +41o (c 0.78, 95% EtOH) after recrystallisation from EtOAc. [Herr et al. J Am Chem Soc 89 4808 1967, NMR: Wiley et al. J Org Chem 44 9 1979.] It is a potent methylating agent for DNA [Bennett & Pegg Cancer Res 41 2786 1981].

ストレプトゾトシン 生産企業

Global(424)Suppliers

ストレプトゾトシン スペクトルデータ(¹HNMR、FT-IR、MS、Raman)

18883-66-4, ストレプトゾトシン キーワード